Dark Mode Light Mode

Owlstone Medical raises $27M to lead the way in non-invasive diagnostic testing

Billy Boyle, CEO of OWLSTONE MEDICAL

Owlstone Medical, based in Cambridge, positions itself as a global leader in non-invasive diagnostics through its Breath Biopsy® technology. By analyzing volatile organic compounds (VOCs) found in breath, the platform enables the early detection of serious diseases and the longitudinal monitoring of patients.

The company is developing several diagnostic tests targeting critical medical needs. These include a screening test for the early detection of lung cancer, the leading cause of cancer-related deaths globally, with 1.8 million deaths annually. Owlstone is also advancing the LIBRA Test, designed to diagnose chronic liver diseases, which account for over 2 million deaths each year. In the field of digestive health, the company has introduced the OMED Health Breath Analyzer, a portable and low-cost device for diagnosing and monitoring conditions such as small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption.

Owlstone’s Breath Biopsy® technology includes proprietary tools such as the ReCIVA sample collection device and the VOC Atlas®, an extensive database of breath biomarkers. These solutions optimize diagnostic accuracy and reliability across diverse clinical applications, while promoting the use of medical devices for at-home care.

Owlstone Medical secured $27M (approximately €22M) in the first close of its Series E funding round, led by Ventura Capital with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation. The funds will support the development of the Breath Biopsy platform, progress clinical trials, and drive the global commercialization of the LIBRA and OMED Health tests.

Previous Post

€26 million for Maki: the AI redefining recruitment KPIs

Next Post

Shippeo raises €29 million to enhance logistics data quality

Advertisement